Filing Flows › Evommune (EVMN) › Recalls, complaints & regulation
Evommune (EVMN): clinical trials
Evommune (EVMN) beyond its filings: 1 active clinical trial.
Evommune's latest quarter
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Evommune have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.